The University Hospital of Ceuta participates in a multicenter and international clinical trial on Alzheimer’s disease. disease
Spain, February 2013.- el Hospital Universitario de Ceuta is participating in a multicenter and international clinical trial on Alzheimer’s whose results are still promising. The University Hospital of Ceuta is one of the only four participating hospitals nationwide from among a total of 72 centres around the world. This clinical trial, which is in phase III, will apply on some 800 people with Alzheimer’s disease; about 15 users in the health Area of Ceuta.
Wednesday, 6 February, the Regional Director of the National Institute of health management (Ingesa), Fernando Pérez-Padilla, together with the research team participating in the study: it Coordinator, Dr. David GarcÃa, and the ugly in neurology Dr. Rafael Merino, investigador principal, and Dr. Benito Galeano, co-investigator, unveiled the first steps of this transcendental via research.
The Territorial Director wanted to highlight that this essay is a breakthrough medical research in Ceuta, in keeping with the physical and human capital of the Hospital Universitario de Ceuta, which celebrates its third anniversary coinciding with this presentation ”.
Enough encouraging are the data that we have so far, as there are figures showing that in phase II of the study, about 450 patients, slowed the progression of the disease almost 90% and almost 20% of the patients improved cognitive functions ”, went on to say.
Moreover, the Coordinator of the study in Ceuta, Dr. David GarcÃa, said that this phase of the study to evaluate the efficacy and safety of it. You have to be very cautious because at any moment you can twist. In principle, they are excited because so far they have obtained very good results but more importantly if cabe is that our Hospital begin to participate in this type of testing. We hope that this will be the first of many others, also on other diseases ”.
The principal investigator, Dr. Rafael Merino, said some details of the study, since it is focused on patients with Alzheimer’s disease of mild or moderate grade, which will take into account the inclusion criteria will be very strict. It is a molecule that is an inhibitor of tau protein aggregation. This is a protein that is normally expressed in the neurons of the central nervous system. It is inhibiting the abnormal aggregation of this protein. When the aggregation of this protein, there is a dysfunction of neurons and neuronal death in some areas of the brain ”.
Finally, Dr. Benito Galeano said the relevance for a hospital University of developing the area research and, more specifically, to participate in this important trial that we hope to be successful and help improve the quality of life of these patients and may have less disability in the future ”.
